For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
After finishing at $5.82 in the prior trading day, Candel Therapeutics Inc (NASDAQ: CADL) closed at $5.79, down -0.52%. In other words, the price has decreased by -$0.52 from its previous closing price. On the day, 0.33 million shares were traded. CADL stock price reached its highest trading level at $5.92 during the session, while it also had its lowest trading level at $5.7.
Ratios:
Our goal is to gain a better understanding of CADL by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.04 and its Current Ratio is at 7.04. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.01.
On February 20, 2025, Citigroup started tracking the stock assigning a Buy rating and target price of $25.
On February 19, 2025, Canaccord Genuity started tracking the stock assigning a Buy rating and target price of $20.Canaccord Genuity initiated its Buy rating on February 19, 2025, with a $20 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jul 28 ’25 when Nichols William Garrett sold 937 shares for $6.98 per share. The transaction valued at 6,540 led to the insider holds 52,493 shares of the business.
Nichols William Garrett sold 781 shares of CADL for $3,936 on Jun 30 ’25. The Chief Medical Officer now owns 52,493 shares after completing the transaction at $5.04 per share. On Jun 30 ’25, another insider, WILLIAM GARRETT NICHOLS, who serves as the Officer of the company, bought 3,593 shares for $4.90 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CADL now has a Market Capitalization of 317842624 and an Enterprise Value of 225496624.
Stock Price History:
The Beta on a monthly basis for CADL is -0.90, which has changed by -0.082408845 over the last 52 weeks, in comparison to a change of 0.16844666 over the same period for the S&P500. Over the past 52 weeks, CADL has reached a high of $14.60, while it has fallen to a 52-week low of $3.79. The 50-Day Moving Average of the stock is -2.48%, while the 200-Day Moving Average is calculated to be -9.63%.
Shares Statistics:
The stock has traded on average 850.56K shares per day over the past 3-months and 530050 shares per day over the last 10 days, according to various share statistics. A total of 54.89M shares are outstanding, with a floating share count of 37.78M. Insiders hold about 31.18% of the company’s shares, while institutions hold 37.39% stake in the company. Shares short for CADL as of 1755216000 were 6742773 with a Short Ratio of 7.93, compared to 1752537600 on 6555372. Therefore, it implies a Short% of Shares Outstanding of 6742773 and a Short% of Float of 15.509999999999998.
Earnings Estimates
The dynamic stock of Candel Therapeutics Inc (CADL) is currently attracting attention from 2 analysts actively involved in rating its market status.The consensus estimate for the next quarter is -$0.28, with high estimates of -$0.23 and low estimates of -$0.33.
Analysts are recommending an EPS of between -$0.38 and -$0.77 for the fiscal current year, implying an average EPS of -$0.57. EPS for the following year is -$0.44, with 1.0 analysts recommending between -$0.44 and -$0.44.
